Acadia Pharmaceuticals ACAD Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's accrued expenses?
- Acadia Pharmaceuticals (ACAD) reported accrued expenses of $293.28M in Q1 2026.
- How has Acadia Pharmaceuticals's accrued expenses changed year-over-year?
- Acadia Pharmaceuticals's accrued expenses increased by 3.1% year-over-year, from $284.44M to $293.28M.
- What is the long-term trend for Acadia Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accrued expenses has grown at a 22.3% compound annual growth rate (CAGR), from $97.47M to $266.21M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.